-
-
On Feb. 15, 2011, a 30-month-old U.S.-born child of Somali descent developed a skin rash 14 days after returning from a trip to Kenya and 1 day after visiting a child care center.
-
Basically, people now feel nothing is safe to eat. They don't know what choices to make.
-
The April 14 issue of the New England Journal of Medicine contains two articles on boceprevir, a new designer molecule that has demonstrated a dramatic improvement in outcomes for patients with genotype 1 hepatitis C.
-
ZOSTAVAX®, which had previously received FDA approval for prevention of herpes zoster (HZ) and post-herpetic neuralgia in individuals 60 years of age and older, had its approval extended to include people 50-59 years of age on March 24, 2011.
-
A retrospective study was conducted of 563 children who presented over the last decade to two pediatric immunodeficiency centers in the United Kingdom.
-
GARDASIL® (Human Papillomavirus Quadrivalent [Types 6, 11, 16, 18] Vaccine, Recombinant) previously received FDA approval for prevention of cervical, vulvar, and vaginal cancer and associated precancerous lesions, and for prevention of genital warts in males and females 9-26 years of age.
-
In a prospective observational study, investigators of the HIV-CAUSAL Collaboration evaluated data from participating HIV clinics in Europe and the U.S. Veterans Administration system to determine the optimal CD4+ T cell count at which combination antiretroviral therapy (cART) should be initiated.
-
Coccidioidal infections are always unique the travel history often provides the right clue for the practitioner but first you have to think to ask the right question.
-
In this issue: Calcium supplements and MI; birth control pills and VTE; ACE inhibitors and breast cancer risk; spending on pharmaceuticals; and FDA actions.
